Amgen Adjusts Strategy Amid MFN Price Ceiling Challenges
PILLAR DIAGNOSTIC // WEEK 12
“A binding MFN price ceiling on key products is constraining revenue upside against still-aggressive guidance, and with sentiment yet to reflect this map blocker, further repricing is likely as investors reassess growth prospects.”
Proposed action
Trim long exposure or hedge ahead of upcoming catalysts
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
Quarterly revenues rose 8.6% to $9.87 billion despite a 3.3% EPS contraction to $4.74, while full-year 2026 guidance calls for $37.0–38.4 billion in revenue and GAAP EPS of $15.45–16.94, driven by growth from Repatha, Evenity, Tezspire, oncology and rare-disease drugs, and biosimilars offsetting Prolia/Xgeva erosion, pricing headwinds and 340B utilization; pipeline investment centers on the obesity candidate MariTide and other late-stage assets.
THE MAP
Structure & constraints
Most-Favored-Nation pricing now covers 54 drugs from six companies via a cash-only portal matching the lowest global rates, even as Democratic leaders demand full disclosure of secret MFN agreements and question whether those deals will yield real Medicaid savings.
THE MOOD
Consensus & positioning
Investor optimism is underpinned by raised fair-value targets, anticipation of upcoming data catalysts in obesity and cardiometabolic assets, and technical momentum signals reinforcing a bullish narrative.